Homepage

Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M
MPN RESEARCH FUNDED
0
RESEARCHERS SUPPORTED
0
PROJECTS FUNDED

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • What to Know About the FDA Approval of momelotinib

    MPN NEWS | September 21, 2023

    MPN Research Foundation is pleased to share the news of the US FDA approval of momelotinib for the treatment of myelofibrosis patients with anemia whether they have had prior treatment or not. Let’s break down what the approval of this new drug means for those impacted by MPNs: • Treatment options are expanding. Janus kinase (JAK) inhibitors… Read More »What to Know About the FDA Approval of momelotinib

    READ MORE

    Q&A with MPN Pioneer Andrew Schafer, MD

    MPN NEWS | September 14, 2023

    “From the outset, we recognized that outstanding care of MPN patients required not just hematologists (who would be their primary doctors) but also the participation of other specialists who had expertise in the complications of MPNs, such as cardiologists, neurologists, vascular surgeons, interventional radiologists, dermatologists, infectious disease specialists, gastroenterologists, and rheumatologists.”         … Read More »Q&A with MPN Pioneer Andrew Schafer, MD

    READ MORE

    Current and Emerging Therapies

    MPN NEWS | August 25, 2023

    Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematologic malignancies characterized by the abnormal proliferation of blood cells in the bone marrow. MPNs cause significant morbidity in the form of burdensome symptoms, potentially fatal cardiovascular complications, progression to more aggressive disease, and over time, can evolve to… Read More »Current and Emerging Therapies

    READ MORE
  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With an investment today, you can accelerate research for better outcomes.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

     INVEST NOW

    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    “Under the Microscope”